Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Verapamil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verapamil SCHEMBL29450374 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL30402443 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29450364 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL16742 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29064783 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL29423253 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL33297 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29440902 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL1902363 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| (S)-Verapamil SCHEMBL14874635 | 1.00 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433899-B2 | Therapeutics and method for treating osteoarthritis | CALOSYN PHARMA INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250120937-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2023015045-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-110590717-B | Polysubstituted ketene imine and synthetic method thereof | 上海大学 | 2022-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120937-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CA2, SLC16A1, ORAI1 | CACNA1C 30/4885CACNA1F 35/4885CACNA1D 34/4885 |
| US-12433899-B2 | Therapeutics and method for treating osteoarthritis | CA2, SLC16A1, ORAI1 | CACNA1C 29/4885CACNA1F 35/4885CACNA1D 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.